|Reference : The earlier the smaller the better for natalizumab-associated PML: in MRI vigilance v...|
|Scientific journals : Article|
|Human health sciences : Neurology|
|The earlier the smaller the better for natalizumab-associated PML: in MRI vigilance veritas ?|
|PHAN BA, Remy [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]|
|Belachew, Shibeshih [Université de Liège - ULg > Département des sciences cliniques > Neurologie >]|
|Outteryck, Olivier [Salengro Hospital, Université de Lille Nord de France, CHRU Lille, France > Neurology > > >]|
|Moonen, Gustave [Université de Liège - ULg > Département des sciences cliniques > Neurologie >]|
|Sindic, Christian [Cliniques Universitaires Saint-Luc, UC Louvain, Brussels > Neurologie > > >]|
|Vokaer, Mathieu [Clinical Neuroimmunology Unit, University Hospital Erasme, Brussels > Neurology > > >]|
|Vermersch, Patrick [Salengro Hospital, Université de Lille Nord de France, CHRU Lille, France > Neurology > > >]|
|Lippincott Williams & Wilkins|
|Yes (verified by ORBi)|
|[en] PML ; Natalizumab ; MRI ; JC virus ; Multiple sclerosis|
|[en] Natalizumab-associated progressive multifocal leukoencephalopathy (N-PML) in multiple sclerosis (MS) is due to CNS infection by the opportunistic JC virus (JCV). As of december 2011, 193 confirmed cases of N-PML have been observed, giving rise to an overall risk of approximately 0,202%. N-PML pathogenesis remains partially elusive although risk factors have now been clearly delineated. In patients with prior JCV infection detected by serum anti-JCV antibodies, duration of therapy and prior use of immunosuppressants (IS) increase the risk of N-PML. The clinical outcome of MS patients who developed N-PML was highly variable, ranging from asymptomatic case to varying degrees of neurological disability or even death. It was also observed in real life setting that the earlier N-PML was diagnosed and treated, the better was the clinical outcome. Clinical vigilance is now considered as the established cornerstone of PML risk-management algorithm.
Here we present early MRI features of 4 out of 8 N-PML cases, which were observed in Wallonia-Brussels and Northern France in more than 4 years of post-marketing utilization of natalizumab for both regions. We are not aware of the specific context and outcome of the 4 other N-PML cases, which were diagnosed and treated in other centers. The reported cases emphasize that (i) N-PML can have a long presymptomatic course while still being clearly detectable with MR imaging, (ii) N-PML can have a benign outcome provided it is diagnosed and treated early, (iii) a clinically symptomatic N-PML may be a further advanced infection with a poorer prognosis, and (iv) periodic brain MR scans, particularly in high risk situations, are likely to provide earlier detection of N-PML and better outcomes.
|File(s) associated to this reference|
All documents in ORBi are protected by a user license.